NCT06336681Completed
Inspiratory Muscle Training on The Severity of Exercise-Induced Bronchoconstriction and Time-Trial Performance (IMT_EIB)
Effect of Flow-Resistive Inspiratory Muscle Training on The Severity of Exercise-Induced Bronchoconstriction and Cycling Time-Trial Performance
Source: ClinicalTrials.gov · Last updated 12 May 2026
Brief summary (registry, in English)
Due to the lack of studies examining the impact of inspiratory muscle training (IMT) on the severity of exercise-induced bronchoconstriction (EIB) and exercise performance, the specific aim of this study is to assess the efficacy of flow-resistive IMT on EIB severity and symptoms, short-acting beta-2-agonist medication use, operating lung volumes, respiratory and limb locomotor muscle deoxygenation during constant-load cycling exercise, exertional dyspnea, and cycling time-trial performance.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 7 Mar 2024
- Start date
- 10 Feb 2022
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Indiana University
- Diseases
- Asthma
- NCT number
- NCT06336681
What you commit to
- Study type: Interventional
- Participants enrolled: 15
- From 10 Feb 2022 to the primary completion date, 30 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently taking asthma maintenance medications (e.g., corticosteroids and leukotriene modifiers)
Other illness
- History of smoking or recreational smoking, cardiovascular disease, renal disease, neurological disease, and metabolic disease.
- Taking selective serotonin reuptake inhibitors (SSRI)'s (antidepressants and anxiety medication), attention-deficit hyperactivity disorder (ADHD) medication, and chronically consume pain medication (Aleve, Tylenol, cannabidiol (CBD), etc.).
- Has had or is positive for COVID-19.
Other
- Any injuries in the past 6 months.
- Resting blood pressure of \> 130 mmHg systolic or 90 mmHg diastolic.
- Resting Pulse rate of \> 100 bpm.
- Regularly consuming fish oil supplements or eating more then one fish meal per week
Who the study is looking for
- Male and female, between the ages of 18 to 35 years.
- Required to be a competitive recreational or college athlete and have at least 1-2 years of cycling or biking experience.
- Body Mass Index (BMI) of 18.5 to 28 kg/m\^2
- Considered "moderately to highly active" by the International Physical Activity Questionnaire (IPAQ).
- Have clinically treated mild to moderate persistent asthma and/or exercise-induced bronchoconstriction (EIB), with a resting forced expiratory volume in 1 second (FEV1) \> 65% of predicted.
- A ≥ 10% drop in FEV1 after eucapnic voluntary hyperpnea (EVH).
- Prescribed short-acting β2-agonists (SABAs) by a physician.
- Comfortable not taking SABA before experimental visits.
Age in the registry: 18 years to 35 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| School of Public Health-Bloomington Coordinator of this site? Confirm its status | Bloomington | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.